Publication:
Investigation of Arenesulfonyl-2 as Potent Carbonic Anhydrase Inhibitors

dc.authorscopusid57212168005
dc.authorscopusid7003950201
dc.authorscopusid23027537500
dc.authorscopusid23013520200
dc.authorscopusid7102904152
dc.contributor.authorAbdel-Aziz, A.A.-M.
dc.contributor.authorEl-Azab, A.S.
dc.contributor.authorEkinci, D.
dc.contributor.authorŞentürk, M.
dc.contributor.authorSupuran, C.T.
dc.date.accessioned2020-06-21T13:51:01Z
dc.date.available2020-06-21T13:51:01Z
dc.date.issued2015
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Abdel-Aziz] Alaa A.M., Department of Pharmaceutical Chemistry, College of Pharmacy, Riyadh, Riyad, Saudi Arabia, Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura, Dakahlia, Egypt; [El-Azab] Adel S., Department of Pharmaceutical Chemistry, College of Pharmacy, Riyadh, Riyad, Saudi Arabia, Department of Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo, Cairo, Egypt; [Ekinci] Deniz, Department of Agricultural Biotechnology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Şentürk] Murat, Department of Chemistry, Aǧrı İbrahim Çeçen Üniversitesi, Agri, Agri, Turkey; [Supuran] Claudiu T., NEUROFARBA Department, Università degli Studi di Firenze, Florence, FI, Italyen_US
dc.description.abstractA series of arenesulfonyl-2-imidazolidinones incorporating methyl, isopropyl, methoxy, halogen and phenyl moieties were prepared and tested as possible inhibitors of two members of the pH regulatory enzyme family, carbonic anhydrase (CA; EC 4.2.1.1). The inhibitory potencies of the compounds against human isoforms hCA I and hCA II were analyzed by an esterase assay with 4-nitrophenyl acetate as substrate, and the inhibition constants (K<inf>I</inf>) were calculated. Most compounds investigated here exhibited micromolar inhibition constants against the two isoenzymes. K<inf>I</inf> values were in the range of 10.2-40.6 μM for hCA I and of 13.1-31.4 μM for hCA II, respectively. Most of the imidazolidinones showed interesting CA inhibitory efficacy, some of them having comparable affinity (for hCA I) as the clinically used sulfonamide acetazolamide (AZA), but their efficacy against hCA II was much lower compared to AZA. © 2014 Informa UK Ltd.en_US
dc.identifier.doi10.3109/14756366.2014.880696
dc.identifier.endpage84en_US
dc.identifier.issn1475-6366
dc.identifier.issn1475-6374
dc.identifier.issue1en_US
dc.identifier.pmid24666299
dc.identifier.scopus2-s2.0-84921311423
dc.identifier.scopusqualityQ1
dc.identifier.startpage81en_US
dc.identifier.urihttps://doi.org/10.3109/14756366.2014.880696
dc.identifier.volume30en_US
dc.identifier.wosWOS:000347956500013
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherInforma Healthcare healthcare.enquiries@informa.comen_US
dc.relation.ispartofJournal of Enzyme Inhibition and Medicinal Chemistryen_US
dc.relation.journalJournal of Enzyme Inhibition and Medicinal Chemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCarbonic Anhydraseen_US
dc.subjectGlaucomaen_US
dc.subjectImidazolidinoneen_US
dc.subjectInhibitoren_US
dc.titleInvestigation of Arenesulfonyl-2 as Potent Carbonic Anhydrase Inhibitorsen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files